N/A N=87 Stress Incontinence Trial With Elitone Device
Stress Urinary Incontinence
Primary: Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes — 52.8; 7.9 percent reduction in leaks/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=94 Stress and the Sympathetic Nervous System in Adults With Depression
Major Depressive Disorder
Primary: Percent of Days Participants Report Stressors — 36; 40 percent of days
N/A N=66 Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department
Diabetic Ketoacidosis
Primary: Patient Recruitment Rate (Feasibility Outcome) — 66 Participants
N/A N=24 Effect of a Rent Subsidy and Mentoring on Youth Transitioning Out of Homelessness
Homeless Persons
Primary: Community Integration Scale Score at 18 Months — 11.3; 10.8; 11.2; 13.2 score on a scale — p=0.18
N/A N=120 A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management
Gut Health · Metabolism · Weight Loss
Primary: Changes in Body Weight. [Baseline to Week 12] — 194.81; 194.35; 194.17; 193.68 Pounds (lbs) — p=<0.0001
Phase 2 N=37 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Phase 2 N=190 A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
Narcolepsy
Primary: Epworth Sleepiness Scale — -5.1; -5.6; -3.3 score on a scale — p=0.024
N/A N=124 Ambispective, Multicentre, Open-label Study Evaluating the Clinical Outcomes of Foot Surgery Using SERF Medical Devices
Foot Diseases
Primary: Reduction of the Patient's Pain and Restoration of Walking — 42.46; 88.44 points
N/A N=34 HOMEStudy: Development of a Home-based Self-delivered Prehabilitation Intervention to Proactively Reduce Fall Risk in Older Adults
Mobility Limitation · Aging
Primary: Walking Speed Change From Baseline — 0.052; -0.026 m/s — p=0.012
Phase 1 N=16 Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
Healthy · Renal Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib — 3450; 2910 nanogram per milliliter (ng/mL)
N/A N=39 FREEZE-AFIB Post-Market Study
Atrial Fibrillation · Atrial Flutter
Primary: Freedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events. — 0 Participants
Phase 2 N=269 Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
Group B Streptococcal Infection
Primary: Concentrations of Immunoglobulin (Ig) G Antibodies Specific to the AlpN Proteins in μg/mL in Cord Blood From Each Baby — 11.12; 5.52; 7.95; 3.51 μg/mL
N/A N=528 Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
Migraine Disorders
Primary: Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) — 23; 167; 63; 217 Participants
Phase 2 N=40 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants
Phase 1 N=9 A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
Healthy
Primary: Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose…